A biopharmaceutical firm dedicated to the acquisition.

This will be the Company's third acceptance of a global Phase 2 clinical trial in China, the first getting for advanced triple-negative breast cancer where the first patient was enrolled the other day at the Cancer Hospital of Chinese Academy of Medical Science in Beijing and the second being for advanced soft tissue sarcoma. More info about the three trials are available at Related StoriesFDA, EMA accept submitting applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lungResearchers reveal new subtypes of invasive lobular carcinomaArgos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinomaKen K.An application for supporting development of vaccines and other countermeasures requires congressional authorization to continue past 2013. Legislation that could reauthorize Task Bioshield and other key biodefense initiatives is definitely winding its way through both chambers of Congress.

Baylor, Select announce closing of jv transaction Baylor HEALTHCARE System and choose Medical Company today announced they have closed their previously announced jv transaction, and that the jv will commence procedures on April 1, 2011. The jv includes a partnership between Baylor Institute for Rehabilitation and choose Physical Therapy Texas that creates a regional rehabilitation network to provide the Dallas-Fort Worthy of metroplex. The jv provides services as an element of the Baylor HEALTHCARE System and its own daily functions will be maintained by Kessler Rehabilitation Solutions, Inc., a Select Medical affiliate and firm of Kessler Institute for Rehabilitation.